Merck, Gilead Report Mixed Outcomes in Key Lung Cancer, HIV Studies

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial - Gilead Sciences (NASDAQ:GILD), Merck & Co (NYS

On Monday, Gilead Sciences Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda in previously untreated metastatic non-small cell lung cancer with high PD-L1 expression, following a Data Monitoring Committee review of progression-free survival and interim overall survival data. While the combo showed a numerical improvement in progression-free survival,…

Gilead and Merck's latest trial success and flop

Today's biotech news includes AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and Gilead and Merck's trial results

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow

Partners Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely braced for impact, according to Wall Street. The companies ...